文献速递中医内科中药与中成药合理使用

芍药甘草汤治疗维持性血液透析肌肉痉挛的前瞻性随机交叉对照试验

Shaoyao-Gancao decoction for the treatment of muscle cramps in maintenance hemodialysis: A prospective randomized crossover controlled trial.
PubMed 文献 · J Ethnopharmacol · 2025-04-07

本研究采用随机交叉对照设计,纳入62例每周至少发生2次肌肉痉挛的维持性血液透析患者,评估芍药甘草汤(SG)的疗效与安全性。结果显示,4周干预后SG序列痉挛频率未调整斜率较对照序列显著降低2.08(95%CI:-3.16,-1.00;p<0.001),且A-VAS、C-VAS和CR亦优于对照。SG耐受性良好,可能通过适度降低透析前后血钾水平(透析前未调整斜率差-0.27,95%CI:-0.45,-0.09;p=0.004)发挥作用。

要点

  • 芍药甘草汤可显著降低维持性血液透析患者肌肉痉挛频率。
  • SG对痉挛相关VAS评分及受累身体区域亦有改善作用。
  • SG耐受性良好,但需监测血钾变化。

核心结论

  • 芍药甘草汤可显著缓解维持性血液透析患者的肌肉痉挛,且安全性可靠。
  • 其作用可能部分归因于适度降低血钾水平并维持在理想范围内。

研究设计与样本

  • 前瞻性随机交叉对照试验,于广东省中医院血液透析中心开展。
  • 纳入年龄18-80岁、每周至少发生2次肌肉痉挛的维持性血液透析患者;筛查81例,随机分配62例(A组32例,B组30例),最终60例完成研究。
  • 研究流程:2周导入期后,第1研究期A组接受SG、B组继续标准透析4周;经2周洗脱期后,第2研究期交换处理,B组接受SG、A组对照4周。

主要发现

  • 痉挛频率(FC)基线:SG序列5.92(SE 0.39),对照序列4.37(SE 0.39)。
  • 4周干预期间FC未调整斜率:SG序列-2.37(SE 0.34),对照序列-0.28(SE 0.33),序列间差异-2.08(95%CI:-3.16,-1.00;p<0.001)。
  • A-VAS、C-VAS和CR在序列间比较亦支持SG组显著改善。
  • 亚组分析显示,无糖尿病患者接受SG干预存在显著交互作用,OR=12.50(95%CI:2.23,70.19;P=0.049)。
  • 事后分析显示SG对透析前后血钾有适度降低作用,透析前未调整斜率差-0.27(95%CI:-0.45,-0.09;p=0.004)。

关键数值与推荐

  • 主要疗效终点为痉挛频率(FC)的变化,次要终点包括累计痉挛时间(CT)、平均痉挛时间(AT)、累计VAS评分(C-VAS)、时间平均VAS评分(A-VAS)、最差VAS评分(W-VAS)及累计受累身体区域(CR)。
  • 安全性评价包括不良事件(AEs)、严重不良事件(SAEs)及血清尿酸、AST、CO2CP、肌酸激酶(CK)、CK-MB、LDH、HBDH、钾、钠、氯、钙、镁、磷等实验室指标。

临床怎么用

  • 对于维持性血液透析相关肌肉痉挛患者,可考虑在监测血钾的前提下使用芍药甘草汤。
  • 治疗期间应关注痉挛频率、VAS评分及受累身体区域的变化以评估疗效。
  • 需定期监测血钾等电解质及肌酶谱,确保用药安全。

局限性

  • 研究为单中心试验,样本量较小(62例随机,60例完成)。
  • 干预周期较短(每期4周),长期疗效与安全性尚未明确。
  • 研究纳入人群为18-80岁维持性血液透析患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Shaoyao-Gancao Decoction (SG), a traditional Chinese herbal formula comprising Paeoniae Radix Rubra (Paeonia lactiflora Pall., root) and Glycyrrhizae uralensis (Glycyrrhiza uralensis Fisch., root and rhizome), is renowned for its effectiveness in alleviating muscle cramps and pain. Significantly, both preclinical and clinical studies have unveiled its exceptional potential as a pain-relieving agent and muscle relaxant. Moreover,its efficacy and safety in patients undergoing maintenance hemodialysis (HD) related muscle cramps remain undetermined. AIM OF THE STUDY: To verify the effectiveness and safety of SG in patients with HD-related muscle cramps. MATERIALS AND METHODS: A randomized, crossover controlled design was conducted in this trial. This study involved patients aged 18-80 undergoing HD at the hemodialysis center of Guangdong Provincial Hospital of Traditional Chinese Medicine, experiencing muscle cramps at least twice weekly. Following a 2-week run-in period, patients who provided informed consent were randomly allocated to Group A and Group B. During study period 1, Group A patients received SG while Group B continued their standard HD treatment for 4 weeks. After a 2-week washout period, the treatments were switched in study period 2, with Group B receiving SG and Group A acting as the control for another 4 weeks. Data from participants in Group A during period 1 and from Group B during period 2 comprised the SG sequence, whereas the control sequence include data from Group A during period 2 and Group B during period 1. The primary efficacy endpoint was the change in frequency of cramps (FC), while secondary endpoints including changes in cumulative time of cramps (CT), average time of cramp (AT), cumulative VAS score (C-VAS), time-average VAS score (A-VAS), worst VAS score (W-VAS) and Cumulative affected body regions (CR). The safety evaluation of SG involved monitoring adverse events (AEs), serious adverse events (SAEs), and conducting serological testing, which included the serum uric acid, AST, CO2CP, creatine kinase (CK), Creatine Kinase- Myocardial Band (CK-MB), LDH, HBDH, potassium, sodium, chloride, calcium, magnesium and phosphorus as safety indices. The results of the serological testing were submitted to a specialized data analyst to identify AEs according to the Medical dictionary for Regulatory Activities (MedDRA) central coding dictionary. Statistical analyses were conducted using paired t-test, repeated measures analysis of covariance (RANCOVA) models and generalized linear mixed models. The post-hoc analysis utilizing independently measured continuous laboratory data for CK, CK-MB, LDH, potassium, calcium, and magnesium, employing both unadjusted and adjusted linear mixed-effects models to assess the effects of SG and obtain the objective results. RESULTS: This study was conducted from November 8th, 2021 to November 1st, 2022. Of the 81 patients screened, 62 were randomly assigned to Group A (32 cases) and Group B (30 cases). No statistically significant differences were found in demographic and clinical characteristics between Group A and Group B. A total of 60 participants completed the study. The baseline level of FC was 5.92 (standard error [SE] 0.39) for the SG sequence and 4.37 (SE 0.39) for the control sequence. The unadjusted slope for FC was -2.37 (SE 0.34) in the SG sequence and -0.28 (SE 0.33) in the control sequence, with a statistically significant difference of -2.08 (95 % confidence interval [CI]: -3.16, -1.00; p < 0.001) between sequences over the 4-week intervention period. Statistical analyses also favored SG in terms of A-VAS, C-VAS and CR between sequences, indicating a significant reduction in muscle cramps among HD patients. Subgroup analyses revealed a subtle yet statistically significant interaction among participants without diabetes who underwent the SG intervention, with an odds ratio of 12.50 (95 % CI: 2.23, 70.19, P = 0.049). The safety analysis indicates that SG is well-tolerated in patients receiving high doses and has a reliable safety profile. The results of the post-hoc analysis revealed a modest effect on reducing potassium levels in both pre- and post-dialysis, particularly in pre-dialysis, with a difference of -0.27 (95 % confidence interval [CI]: -0.45, -0.09; p = 0.004) in the unadjusted slopes for pre-dialysis potassium. CONCLUSIONS: This study supports the significant effectiveness of SG in alleviating muscle cramps among maintenance HD patients. These effects may be attributed to the moderate reduction of potassium levels while maintaining them within the ideal range achieved by SG. Our study provides valuable evidence on the safety and efficacy of using Chinese medicine to mitigate adverse symptoms of HD.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li C, Lin Q, Xu P, et al. Shaoyao-Gancao decoction for the treatment of muscle cramps in maintenance hemodialysis: A prospective randomized crossover controlled trial. J Ethnopharmacol. 2025. PMID: 40204247. doi:10.1016/j.jep.2025.119758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。